← Back to Search

Radiation

Stereotactic Ablative Radiosurgery for Lung Cancer (GPS Trial)

N/A

Waitlist Available

Research Sponsored by CancerCare Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult ≥ 18 years of age who is surgically inoperable, or refusing surgical management

Upper lobe tumors are eligible for trial participation if the tumor has a demonstrated tumor motion of ≥1 cm in any axis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1,2, and 3 year

Awards & highlights

GPS Trial Summary

This trial is for patients with early stage lung cancer or a single pulmonary metastasis. Three tumor locator beacons are placed in the small bronchial airways near the tumors. This allows for smaller treatment volumes of Stereotactic Ablative Radiosurgery (SABR) and more precise delivery of radiotherapy.

Who is the study for?

This trial is for adults over 18 with early-stage Non-Small Cell Lung Cancer or a single lung metastasis who can't have surgery or choose not to. They must be able to undergo bronchoscopy, have decent lung function (DLCO ≥35%, FEV1 ≥0.8L), and an ECOG status of 0-2, indicating they are relatively active. Tumors should be in the middle/lower lobes of the lung but not too close to the chest wall or main airways.Check my eligibility

What is being tested?

The study tests a high precision radiotherapy called Stereotactic Ablative Radiosurgery (SABR) using real-time tumor tracking & respiratory gating for treating lung tumors. Patients will have locator beacons placed near their tumors to guide treatment, aiming for greater accuracy and less damage to healthy tissue.See study design

What are the potential side effects?

While specific side effects aren't listed here, SABR treatments like this may cause fatigue, shortness of breath, skin reactions at the treatment site, coughing up blood, and could potentially worsen existing lung conditions.

GPS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am over 18 and cannot or will not have surgery for my condition.

Select...

My upper lobe tumor moves 1 cm or more.

Select...

I can take care of myself and am up and about more than half of my waking hours.

Select...

My lung cancer is in an early stage and located in the middle or lower lobes, or I have a single small lung metastasis.

GPS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1,2, and 3 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1,2, and 3 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1,2, and 3 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean within patient difference in PTV volumes

Secondary outcome measures

Acute and late toxicity assessment using the Common Terminology Criteria for Adverse Events (CTCAE version 4.0)

Overall Survival

Patient self-reported quality of life

+3 more

GPS Trial Design

1Treatment groups

Experimental Treatment

Group I: Real-Time Position Transponder BeaconsExperimental Treatment1 Intervention

Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

CancerCare ManitobaLead Sponsor

28 Previous Clinical Trials

5,640 Total Patients Enrolled

Varian Medical SystemsIndustry Sponsor

58 Previous Clinical Trials

3,711 Total Patients Enrolled

Media Library

Calypso Guided High Precision Stereotactic Ablative Radiosurgery (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT03322072 — N/A

Non-Small Cell Lung Cancer Research Study Groups: Real-Time Position Transponder Beacons

Non-Small Cell Lung Cancer Clinical Trial 2023: Calypso Guided High Precision Stereotactic Ablative Radiosurgery Highlights & Side Effects. Trial Name: NCT03322072 — N/A

Calypso Guided High Precision Stereotactic Ablative Radiosurgery (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03322072 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must be met in order to partake in this medical experiment?

"This trial is open to adults, aged 18-85, with a diagnosis of non-small cell lung cancer. A maximum of 28 participants can enrol in the study."

Answered by AI

How many individuals are actively participating in this clinical experiment?

"Affirmative. The clinical trial, initially advertised on November 23rd 2017 and last updated on January 26th 2021 is actively recruiting for participants at two distinct medical sites with a need of 28 individuals in total."

Answered by AI

Is enrollment being permitted for individuals below the age of 85 in this experiment?

"Adherence to the eligibility requirements of this trial mandates that participants are between 18 and 85 years old."

Answered by AI

Is there an open enrollment for this experiment currently?

"Clinicaltrials.gov confirms that this medical study, initially posted on November 23rd 2017 and recently updated on January 26th 2021 is seeking patient enrolment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating

Dr. Julian Kim 2017. "Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03322072.

All > Sbrt